[<sup>18</sup>F]FAPI-42 PET/CT in differentiated thyroid cancer: diagnostic performance, uptake values, and comparison with 2-[<sup>18</sup>F]FDG PET/CT.
prospective_cohort · Level II
Where this comes from
- Record sourced from PubMed, PMID 36495325.
- Also identified by DOI 10.1007/s00259-022-06067-2 and PMC identifier 9931817.
- Licence recorded as CC BY.
- The licence permits redistribution, so the abstract is shown in full and the full text is available from the publisher.
Abstract
This study aimed to assess the diagnostic performance of [<sup>18</sup>F]FAPI-42 PET/CT and compare it with that of 2-[<sup>18</sup>F]FDG PET/CT in patients with differentiated thyroid cancer (DTC) with biochemical elevations in Tg or anti-Tg antibodies. A total of 42 patients with DTC with biochemical elevations in Tg or anti-Tg antibodies underwent [<sup>18</sup>F]FAPI-42 PET/CT as part of this study; of which, 11 additionally underwent 2-[<sup>18</sup>F]FDG PET/CT within 7 days. Images were semi-quantitatively and visually interpreted, and the quantity, location, and uptake values of lesions were noted. The diagnostic capacity of [<sup>18</sup>F]FAPI-42 PET/CT and biomarkers affecting the uptake of [<sup>18</sup>F]FAPI-42 were evaluated. In addition, the diagnostic performance and uptake of [<sup>18</sup>F]FAPI-42 and 2-[<sup>18</sup>F]FDG were compared, and the correlation between lesion diameter and quantitative parameters was investigated. A total of 161 lesions were detected in 27 (64%) patients on [<sup>18</sup>F]FAPI-42 PET/CT. FAPI-positive local recurrence showed the highest uptake intensity, followed by lymphatic, other site-associated (bone and pleura), and pulmonary lesions (mean SUV<sub>max</sub>, 4.7 versus 3.7 versus 3.0 versus 2.2, respectively; P < 0.0001). The levels of TSH, Tg, and Tg-Ab did not affect the uptake value of lesions (median SUV<sub>max</sub>: 2.4 versus 3.2, P = 0.56; 2.9 versus 2.4, P = 0.0935; 2.8 versus 2.6, P = 0.0525, respectively). A total of 90 positive lesions were detected in 7 patients using both modalities. All positive lesions showed statistically higher uptake of 2-[<sup>18</sup>F]FDG than that of [<sup>18</sup>F]FAPI-42 (SUV<sub>max</sub>, 2.6 versus 2.1; P = 0.026). However, the SUV<sub>max</sub> of [<sup>18</sup>F]FAPI-42 was higher than that of 2-[<sup>18</sup>F]FDG in local recurrences and lymphatic lesions (SUV<sub>max</sub>, 4.2 versus 2.9 and 3.9 versus 3.4, respectively; P > 0.05). [<sup>18</sup>F]FAPI-42 can be used for detecting lesions and reflecting FAP expression during local recurrence and metastasis in patients with DTC with biochemical elevations in Tg or anti-Tg antibodies. The diagnostic performance of [<sup>18</sup>F]FAPI-42 PET/CT is comparable with that of 2-[<sup>18</sup>F]FDG PET/CT in such patients.
Medical subject headings
- Thyroid Neoplasms
- Adenocarcinoma